Semaglutide triggers significant appetite suppression and improves blood sugar control, leading to faster fat loss than typical dieting alone
Media Cover Scripps Study of GLP-1 Dose Frequency Read the New York Times article: Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds Watch the NBC7 report: Scripps Clinic Doctors Find Patients Keeping Weight Off After Reducing GLP-1 Dosage Watch the CBS 8 report: Scripps Internal Medicine Specialist Discusses the Findings of a New GLP-1 Treatment Study Media Contact Keith Darce 858-678-7121 [email protected]
By using simple methods and keeping track of your readings, you can catch any issues early and take steps to address them
A study of GLP-1 users found that those emphasizing whole foods experienced better energy levels and fewer deficiency symptoms than those eating processed alternatives
The GLP-1s taken by patients in the study included the newer drugs semaglutide, or Ozempic, and tirzepatide, or Mounjaro, as well as any of the older GLP-1s including liraglutide, or Victoza, and exenatide, sold as Byetta and Bydureon BCise, and dulaglutide, or Trulicity
